LEDGER
← All instruments

PM

SP100NYSE

Philip Morris International Inc.

Consumer Defensive · Tobacco · United States

$182.27
+2.58% today
Mkt Cap
$284.08B
P/E
25.64×
Fwd P/E
19.98×
Div Yield
3.23%
Beta
0.405×
52W Range
78.8%
Company profileSource: provider

Philip Morris International Inc. operates as a tobacco company. The company offers cigarettes and smoke-free products, including heat-not-burn, e-vapor, and oral nicotine products under the IQOS, VEEV, and ZYN brands; and consumer accessories, such as lighters and matches. It also offers wellness products. The company was incorporated in 1987 and is headquartered in Stamford, Connecticut.

www.pmi.com
By the numbersComputed from live metrics

Shares trade at a premium 25.6× trailing earnings, easing to 20.0× on forward estimates. Profitability shows a net margin of 26.7%. Leverage is elevated at 2.5× net debt/EBITDA. Revenue grew 9.1% year-on-year. It yields 3.2% in dividends. The mean analyst target of USD194.86 sits 6.9% above the current price (Buy, 14 analysts).

AI analysisAI-generated · 04 Jul 2026 · claude-opus (research)

business model

Philip Morris International manufactures and sells cigarettes and smoke-free products outside the United States, with a strategy centered on transitioning adult smokers to reduced-risk products. It monetizes brands led by Marlboro in combustible cigarettes and is investing heavily in smoke-free platforms such as IQOS heated tobacco and Zyn oral nicotine pouches.

revenue segments

Revenue comes from combustible tobacco products and a growing smoke-free category (heated-tobacco units and devices, plus oral nicotine products), reported across international geographic regions and, following the Swedish Match acquisition, including a US oral-nicotine presence via Zyn. Smoke-free products are an increasing share of net revenue.

key dependencies

Depends on pricing power to offset volume declines, regulatory acceptance of reduced-risk products, excise-tax regimes, adult-smoker migration to IQOS and oral nicotine, currency movements, and continued investment in device technology and manufacturing capacity.

competitors

Competes with British American Tobacco, Japan Tobacco, Imperial Brands, Altria (in certain product and licensing contexts), and various regional and state-owned tobacco companies, as well as makers of e-cigarettes and alternative nicotine products.

moat

Its moat is built on dominant global cigarette brands, strong pricing power, extensive distribution, and a first-mover lead in heated tobacco and nicotine pouches supported by significant R&D and scientific-regulatory investment. Brand loyalty and scale create high barriers to entry.

risks

Risks include secular decline in cigarette volumes, heavy regulation and taxation of tobacco and nicotine, potential restrictions or bans on smoke-free products, litigation, illicit trade, significant foreign-currency exposure given its non-US footprint, and uncertainty over long-term nicotine-policy trends.

01

Financials & metrics

as of 04 Jul 2026
Valuation
Profitability
Growth
Financial Health
Efficiency
Cash Flow
Per Share
Dividend
Market

Tap any metric for an explanation. provider computedN/A not available from source

02

Dividends

This company does not currently pay a dividend.

03

Analyst assessment

as of 04 Jul 2026
Buy14 analysts
Implied to mean target
+6.9%
Low $171.00High $210.00
Now
$182.27
Low
$171.00
Mean
$194.86
High
$210.00
Rating distribution
Strong Buy 4
Buy 7
Hold 4
Sell 0
Strong Sell 0

Aggregate consensus only. Named per-analyst targets require a premium source and are not shown; the data model is ready to hold them if one is added.

04

Technicals

as of 02 Jul 2026
CloseSMA 50SMA 200Golden cross
SMA 50
$177.85
SMA 200
$167.12
RSI (14)
51.9
MACD
0.64
RSI (14) · overbought > 70 · oversold < 30
05

News

Laying off cigarettes boosts Big Tobacco’s financial vitals
Some stocks are valued almost entirely on distant prospects. Think of SpaceX, whose multi-trillion-dollar valuation bears little relation to...
Financial Times · 21h ago
Read ↗
Philip Morris’ Smoke-Free Products Are Winning With Regulators. They’ll Win With Investors Too.
Margin expansion, sales growth, and a reliable dividend payment make the stock a good bet for volatile times.
Barrons.com · 2d ago
Read ↗
Philip Morris International (PM) Wins First FDA Modified Risk Nod For ZYN Pouches
Philip Morris International (NYSE:PM) received FDA modified risk authorization for its ZYN nicotine pouches. The decision allows the company to market ZYN in the U.S. with claims of lower health risk compared with cigarettes. This is the first time nicotine pouches have obtained modified risk status from the FDA. For Philip Morris International, the FDA ruling is a key regulatory event in its push toward smoke free products. ZYN gives the company a larger foothold in oral nicotine, a...
Simply Wall St. · 2d ago
Read ↗
Zyn’s New ‘Lower Risk’ Label Could Light Up Nicotine Pouches Sales
“It’s a real commercial win but not a new revenue stream out of nowhere,” one analyst said of the new risk claim greenlit by the Food & Drug Administration.
Barrons.com · 3d ago
Read ↗
Sector Update: Consumer Stocks Mixed Late Afternoon
Consumer stocks were mixed late Tuesday afternoon, with the State Street Consumer Staples Select Sec
MT Newswires · 4d ago
Read ↗
Zyn Can Market Itself as Less Harmful Than Cigarettes, FDA Says
U.S. officials are allowing Zyn to market itself as being less harmful than traditional cigarettes, making the product the first nicotine pouch on the market to be granted such a distinction. The Food and Drug Administration announced that 20 different Zyn nicotine pouches—including flavors ranging from cool mint to cinnamon—can carry language stating that using the pouches instead of smoking cigarettes puts users at a lower risk of mouth cancer, stroke, heart disease, lung cancer, emphysema and chronic bronchitis. Zyn nicotine pouches, a product of Swedish Match USA which is owned by Philip Morris International contain no tobacco and are the most popular brand in the U.S. They were granted permission to stay on the market in early 2025, the first pouch to receive the authorization.
The Wall Street Journal · 4d ago
Read ↗
Sector Update: Consumer Stocks Mixed in Afternoon Trading
Consumer stocks were mixed Tuesday afternoon, with the State Street Consumer Staples Select Sector S
MT Newswires · 4d ago
Read ↗
FDA clears PM’s Zyn to market as lower cancer risk than cigarettes in 20 variants
Investing.com -- The FDA issued Modified Risk Tobacco Product (MRTP) orders for 20 ZYN nicotine pouch variants on Tuesday, authorizing Philip Morris International Inc's (NYSE:PM) U.S. unit to explicitly market the pouches as carrying a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis than cigarettes, the first time any nicotine pouch has received such a designation. Philip Morris International is trading at $180.17, down 1.48% on the session despi
Investing.com · 4d ago
Read ↗
Altria vs. Philip Morris International: Which Consumer Goods Stock Is a Better Buy in 2026?
Altria leads U.S. profits, while Philip Morris International expands smoke-free products worldwide. See how their financials and risks stack up for 2026.
Motley Fool · 4d ago
Read ↗
What to Expect From Philip Morris' Q2 2026 Earnings Report
Philip Morris is expected to announce its second-quarter earnings in July, and Wall Street expects the company’s EPS to increase by a single-digit percentage.
Barchart · 5d ago
Read ↗